• Evommune set a late-breaking oral presentation of Phase 2a EVO301 data in moderate-to-severe atopic dermatitis at EADV 2026.
• Results were already disclosed as positive top-line findings earlier in 2026; full data will be presented on Oct. 1 in Vienna.
• Readout supports IL-18 inhibition as a potential new approach in atopic dermatitis, targeting broader inflammatory pathways than Th2-focused therapies.
• Phase 2b dose-ranging study is expected to start in mid-2027, setting up the next development step for EVO301.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609231605BIZWIRE_USPR_____20260923_BW409038) on September 23, 2026, and is solely responsible for the information contained therein.